Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation

• Published in: Pediatric dermatology Vol. 35; no. 5; pp. 616 - 621
• Main Authors: Bowles, Vernon M., VanLuvanee, Lisa Jenkins, Alsop, Hugh, Hazan, Lydie, Shepherd, Katie, Sidgiddi, Srinivas, Allenby, Kent, Ahveninen, Tiina, Hanegraaf, Sharon
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2018; John Wiley and Sons Inc
• Subjects: Administration, Topical; Adolescent; Adult; Animals; Burning; Child; Child, Preschool; Double-Blind Method; Erythema; Female; Follow-Up Studies; Head; Humans; Infant; infestations; Insecticides - adverse effects; Insecticides - therapeutic use; Lice; Lice Infestations - drug therapy; Male; Middle Aged; Original; Pediculus - drug effects; Pediculus humanus; Scalp Dermatoses - drug therapy; Skin; therapy‐topical; Treatment Outcome; Young Adult; therapy-topical; infestations

Background There is a need for better control of head louse infestations. Abametapir is an inhibitor of metalloproteinases critical for louse survival and egg development. The efficacy of abametapir lotion, 0.74%, was assessed for its ability to clear head louse infestations after a single applicati...